Navigation Links
Predicting premature birth possible through markers in mother's blood
Date:4/18/2011

Though more than one in 10 American babies are born prematurely, there have been few clues to predict whether a particular baby is going to arrive too early until now.

A new study suggests that more than 80 percent of pre-term births can be spotted in advance with a blood test taken during the second trimester of a pregnancy.

"What's been missing is a way of assessing risk," said Steven Graves, who directs the chemistry portion of the research at Brigham Young University. "Our approach has been to look at the naturally occurring molecules that are present in women's blood to see if we can identify the peptides and small proteins that are at quantitatively different levels in women who go on to have these complications."

Graves and Dr. Sean Esplin at the University of Utah began their search for molecular clues to pregnancy complications in 2002 and now have something to show for it. Esplin is the lead author on a study that will appear in the May issue of the American Journal of Obstetrics & Gynecology and has been posted online by the journal.

The paper introduces three new peptide biomarkers that, in combination with a few other proteins, can signal high risk of pre-term birth. And it's done by looking at just a drop of blood from a mother who is 24 weeks into a pregnancy. In this study, the researchers tested their method on blood samples from 80 women that went full-term and 80 women whose babies came prematurely.

Knowing she is at high risk for pre-term birth is a big advantage for the mother when it comes to decisions about travel and activity level. Esplin also notes that a new hormone treatment can help a baby stay in the womb a little longer.

"With pre-term birth, if we could even prolong a pregnancy by one or two weeks, we could make a very big impact on the number of babies that survive and make sure that those that survive are healthy," said Esplin, an associate professor of maternal-fetal medicine at the University of Utah and an obstetrician for Intermountain Healthcare. "With just one intervention, we could have a really huge impact."

"Because it identifies these patients in this way, it allows us in the future to design interventional trials," Frias said. "Right now we are almost blind in that standpoint."

The method for predicting pre-term birth is patented by BYU and the University of Utah and has been licensed to a company called Sera Prognostics. The company hopes to have a diagnostic test on the market in the first half of 2012.

"This test may dramatically improve our ability to identify moms at risk for spontaneous preterm birth, which we currently cannot do adequately," said Dr. Antonio Frias, a professor of maternal-fetal medicine at Oregon Health & Science University. Frias was not involved with the research.

If follow-up studies also show positive results, Graves is hopeful that the diagnostic test will earn the support of medical care providers, the FDA and insurers.

"I'm optimistic," Graves said. "My students think it's great to be involved with something that's practical and beneficial to the world around them, as well as being good science."


'/>"/>

Contact: Joe Hadfield
joe_hadfield@byu.edu
801-422-9206
Brigham Young University
Source:Eurekalert

Related medicine news :

1. Predicting serious drug side effects before they occur
2. Progress Reported in Predicting Alzheimers
3. A new method is developed for predicting shade improvement after teeth bleaching
4. Predicting drug responsiveness in cancer patients
5. Predicting Alzheimers Risk in Patients With Cognitive Problems
6. Traditional neurologic exams inadequate for predicting survival of cardiac arrest patients
7. Nasendoscopy proves useful in predicting treatment success in sleep apnea patients
8. Breakthrough in Predicting Invasive Breast Cancer
9. Newer Genetic Info Adds Little to Predicting Breast Cancer
10. MSU scientists develop more effective method of predicting lead-poisoning risk
11. Queens researchers pioneer needle-free test for premature babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 2016 , ... "I had a terrible time trying to get my grandson ... if the nebulizer had a more child-friendly design, then children would be more likely ... patent-pending NEBY to avoid the need to deliver medication via a nebulizer mask. The ...
(Date:12/8/2016)... ... 2016 , ... The West Virginia Medical Institute (WVMI) announced ... name change aligns the entire company with its existing Quality Insights branded projects ... are very proud of the achievements associated with the West Virginia Medical Institute ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , a New ... Conventional Data Capture Methods for Input to Electronic Health Records: A Comparative Usability ... the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s ...
(Date:12/8/2016)... Virginia (PRWEB) , ... December 08, 2016 , ... ... services company offering Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care ... operations and general counsel and Eric Hoessel to vice president of sales. ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016   Hudes Laser ... December featuring the multi-wavelength Astanza Trinity laser and ... specializes in laser tattoo removal, IPL hair removal, ... ultrasound therapy. Hudes Laser Aesthetica is setting high ... and promises to deliver effective, long-lasting ...
(Date:12/9/2016)... 2016 Mitsubishi Tanabe Pharma Corporation (Head Office: ... CEO: Dr. Masayuki Mitsuka ) has presented data ... edaravone intravenously in 10-14 day cycles for 48 weeks ... ALS Functional Rating Scale-Revised (ALSFRS-R). The data were presented ... in Dublin, Ireland . ...
(Date:12/9/2016)... , Dec. 9, 2016  Axovant Sciences ... clinical-stage biopharmaceutical company focused on the treatment of ... data from a Phase 2b trial evaluating treatment ... donepezil, compared with donepezil plus placebo in people ... the addition of intepirdine to treatment was associated ...
Breaking Medicine Technology: